Journal
MOLECULAR CANCER THERAPEUTICS
Volume 5, Issue 11, Pages 2624-2633Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-06-0395
Keywords
-
Categories
Funding
- NCI NIH HHS [P50 CA114747, R24 CA93862, U54 CA119367, R21 CA102123] Funding Source: Medline
- NIBIB NIH HHS [R21 EB001785] Funding Source: Medline
Ask authors/readers for more resources
Drug development is a long process that generally spans about 10 to 15 years. The shift in recent drug discovery to novel agents against specific molecular targets highlights the need for more robust molecular imaging platforms. Using molecular probes, molecular imaging can aid in many steps of the drug development process, such as providing whole body readout in an intact system, decreasing the workload and speeding up drug development/validation, and facilitating individualized anticancer treatment monitoring and dose optimization. The main focus of this review is the recent advances in tumor angiogenesis imaging, and the targets include vascular endothelial growth factor and vascular endothelial growth factor receptor, integrin alpha(v)beta(3), matrix metalloproteinase, endoglin (CD105), and E-selectin. Through tumor angiogenesis imaging, it is expected that a robust platform for understanding the mechanisms of tumor angiogenesis and evaluating the efficacy of novel antiangiogenic therapies will be developed, which can help antiangiogenic; drug development in both the preclinical stage and the clinical settings. Molecular imaging has enormous potential in improving the efficiency of the drug development process, including the specific area of antianglogenic drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available